In this study, we explore the role of the CD47-SIRP alpha interaction on the PV RBC life cycle. Our results show that blocking CD47-SIRP alpha in a PV mouse model due to either anti-CD47 treatment or loss of the inhibitory SIRP alpha-signal corrects the polycythemia phenotype. Anti-CD47 ...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域。该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/6... 查看全部>> 免费获取 收...
当重组小鼠 SIRP alpha/CD172a 浓度为 1 μg/mL 时,100 μL/孔可以结合小鼠 CD47(HY-P78711)。此效果的 ED50 为 0.2544 μg/mL。 研究背景:SIRP α/CD172a 蛋白充当 CD47 的免疫球蛋白样细胞表面受体,促进 PTPN6、PTPN11 和其他结合配偶体从细胞质易位到质膜。该受体在各种细胞过程中发挥着至关重要的...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域.该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/620nm的比值为原始数据.本发明实现了...
kappa/lambda bodies illustrates the power of the dual-targeting approach: A favorable safety profile and pharmacokinetics could be achieved in parallel to potent inhibition of the CD47-SIRP alpha interaction and effective cancer cell killing... K Masternak,Z Johnson,V Buatois,... - 《Cancer Immuno...
CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit 中文名: 中文别名: CBNumber: CB215553531 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit化学性质 ...
Interaction between target cell CD47 and the inhibitory macrophage receptor signal regulatory protein alpha (SIRPalpha) counteracts macrophage phagocytosis... M Olsson,P Bruhns,WA Frazier,... - 《Blood》 被引量: 169发表: 2005年 加载更多来源
CD47/SIRP alpha blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignanciesCD47BlinatumomabCombination therapyPhagocytosisNHLT cell immunotherapies are promising options in leukemia, among which the CD19/CD3-bispecific T cell engager antibody blinatumomab (MT103) ...
VH) and antibody light chain variable domain (VL); the first antigen binding domain is the antibody variable domain capable of realizing the specific binding of the CD47; the second antigen binding domain is the antibody variable domain capable of realizing the specific binding of the SIRP alpha...
CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPalpha /CD47 axis. The agent is a human SIRPalpha fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain...